



EuSARC 2022

26 – 28 May 2022
Pamplona (Spain)

**The Biology of Sarcomas:
From Basic Mechanisms to
Innovative Therapies**



EuSARC

FINAL PROGRAM

Day 1 – Thursday, May 26th 2022

- 18:00 – 18:15 **Opening & Organizational aspects**
Chairs: Fernando Lecanda, Marta Alonso, Ana Patiño
- 18:15 – 19:30 **Keynote Lecture 1**
Dr. Alejandro Sweet-Cordero, MD PhD
«Genomic analysis of osteosarcoma: insights into tumor evolution and therapy response»
- 19:30 - 20:30 **Welcome cocktail & buffet**

Day 2 – Friday, May 27th 2022

- 08:30 - 09:00 **Invited Lecture 1**
Chair : Thomas Grünewald
Dr. Nischalan Pillay MD
«Undifferentiated Sarcomas Develop Through Distinct Evolutionary Pathways»

Novel Targets I

- 09:00 - 09:20 **Oral Presentation 1**
P1: CRISPRi-based genetic screen to identify vulnerabilities in metastatic osteosarcoma
Marta Román
- 09:20 - 09:40 **Oral Presentation 2**
P2: Identification and characterization of key players in the Ewing Sarcoma metastatic process
Sara Sánchez-Serra

09:40 - 09:55 **Oral Presentation 3**
P3: Development and characterization of novel cell-internalizing aptamer against EphA2 receptor
Laura Santana-Viera

09:55 - 10:35 **Coffee Break**

10:40 - 11:10 **Invited Lecture 2**
Chair: Fernando Lecanda
Dr. Robbie Majzner MD PhD
«Unleashing the innate and adaptive immune systems for the treatment of pediatric solid tumors»

Novel treatments based on Immunotherapy

Chair: Marta Alonso

11:10 - 11:30 **Oral Presentation 1**
P4: Expression of Galectin-3 inhibitors from a self-replicating RNA vector as treatment for pediatric osteosarcoma
Guillermo Herrador-Cañete

11:30 - 11:50 **Oral Presentation 2**
P5: YB-1 based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells
Anna Josefina von Ofen

11:50 - 12:05 **Oral Presentation 3**
P6: Local treatment with an oncolytic adenovirus expressing 4-1BBL improves survival and reshapes the tumor microenvironment in osteosarcoma
Virginia Laspidea

12:05 - 12:20 **Oral Presentation 4**
P7: A novel in vitro osteosarcoma 3D model to improve immunotherapies using CAR T cells.
Patricia García Rodríguez

12:20 - 12:35 **Oral Presentation 5**
P8: Keep it quiet: improving tumor homing and efficacy of immunotherapies by using silent cells
Álvaro Morales-Molina

12:35 - 13:45 **Lunch**

13:45 - 14:10 **Invited Lecture 3**
Chair: Fernando Lecanda
Dr Judith V.M. Bovée MD
«Sarcoma modeling for patient specific treatment»

Novel Targets II

Chair: Javier García-Castro

14:10 - 14:30 **Oral Presentation 1**
P9: New mediators of metastasis in Ewing sarcoma
Florencia Cidre-Aranaz

14:30 - 14:50 **Oral Presentation 2**
P10: Memory-like NK cells: a promising therapy for Ewing sarcoma
Carla Martín-Cortázar

14:50 - 15:10 **Oral Presentation 3**
P11: KRAS mutation confers resistance to BET inhibitors in osteosarcoma
Louise Marchandet

15:10 - 15:25 **Oral Presentation 4**
P12: TRIM33 interacts with HSF1 in osteosarcoma development
Morgane Lallier

15:25 - 15:40 **Oral Presentation 5**
P13: Identification of Novel Therapies for Metastatic Soft Tissue Sarcoma
Miriam Arrulo

Novel approaches

15:40 - 15:55 **Oral Presentation 1**
P14: Automated high-content drug screening in zebrafish xenografts identifies effective combination treatments against Ewing sarcoma
Sarah Grissenberger

15:55 - 16:10 **Oral Presentation 2**
P15: Cold Atmospheric Plasma and S3I-201 target tumorigenicity in osteosarcoma
Juan Tornin

16:10 - 16:40 **Coffee Break**

Novel targets III

Chair: Sara Labiano

16:40 - 17:00 **Oral Presentation 1**
P16: Omic profiling of paired ES tumors and metastases to identify key players of disease progression
Mariona Chicón-Bosch

17:00 - 17:20 **Oral Presentation 2**
P17: VEGFA isoform switching is associated with an immunosuppressive tumour microenvironment in soft tissue sarcoma.
William R. English

17:20 - 17:35 **Oral Presentation 3**
P18: The anti-stemness activity of the mithramycin analog EC-8042 in osteosarcoma is mediated by its activity as multi-target inhibitor of NOTCH-1 signaling
Óscar Rafael Estupiñán

17:35 - 17:50 **Oral Presentation 4**
P19: Developing nano-delivery systems to reposition drugs for sarcoma treatment
René Rodriguez

Methods for Discovery

Chair: Nicola Baldini

17:50 - 18:00 **Oral Presentation 1**
P20: Osteosarcoma tumoroids as a model to study extracellular matrix and its role in cancer aggressiveness and response
Sofia Avnet

- 18:00 - 18:10 **Oral Presentation 2**
P21: e-VIEWS; Extracellular Vesicles Investigation for the understanding of Ewing Sarcoma dissemination
Raquel Melero-Fernández de Mera
- 18:10 - 18:20 **Oral Presentation 3**
P22: Relevance of 3D cultures to study the dormancy of osteosarcoma cells
Camille Jubelin
- 18:20 - 18:30 **Oral Presentation 4**
P23: Addressing Doxorubicin Resistance In Bone Sarcomas Using Novel Drug-Resistant Models
Borja Gallego
- 18:30 - 18:40 **Oral Presentation 5**
P24: Liquid-Overlay Technique vs. Hanging Drop: Who wins the trophy of “Best method to generate reproducible spheroids”?
Camille Jubelin
- 18:40 - 18:50 **Oral Presentation 6**
P25: Proof of concept for the use of trained sniffer dogs to detect osteosarcoma
Dzohara Murillo
- 19:15 **Bus for Social Event**
- 19:30 **Social Dinner**

Day 3 – Saturday, May 28th 2022

Therapeutic vulnerabilities I

Chair: Dominique Heymann

- 08:30 - 08:50 **Oral Presentation 1**
P26: Identification of genes responsible for osteosarcomas metastatic evolution by active super enhancers profiling
Benjamin Ory
- 08:50 - 09:10 **Oral Presentation 2**
P27: Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma
Sybille Mitnacht

- 09:10 - 09:30 **Oral Presentation 3**
P28: A novel target of EWS-FLI1, the potassium channel KCNN1, regulates Ewing's sarcoma cell proliferation via intracellular calcium signaling
Franck Verrecchia
- 09:30 - 09:50 **Oral Presentation 4**
P29: Regorafenib inhibits osteosarcoma progression and improves bone parameters in mouse preclinical models
Javier Muñoz-García
- 09:50 - 10:10 **Oral Presentation 5**
P30: Use of TP3, a monoclonal antibody recognizing osteosarcoma-associated cell surface antigen as a potential marker for the detection of circulating cells in osteosarcoma
Dennis Cochonneau
- 10:10 - 10:45 **Coffee Break**

Therapeutic vulnerabilities II

Chair: Agi Grigoriadis

- 10:45 - 11:05 **Oral Presentation 1**
P31: Super-enhancer induced ABC transporter abundance drives resistance to doxorubicin in HOS-MNNG cells.
Robel A. Tesfaye
- 11:05 - 11:25 **Oral Presentation 2**
P32: A personalized medicine approach identified enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma
V. Rey
- 11:25 - 11:40 **Oral Presentation 3**
P33: Macitentan treatment as an adjuvant to bone reabsorption inhibition therapy for metastatic inhibition in Osteosarcoma
Javier Muñoz-García
- 11:40 - 11:55 **Oral Presentation 4**
P34: Role of GPX1 as a stemless and prognostic factor in sarcomas
Carmen Huergo
- 11:55 - 12:10 **Oral Presentation 5**
P35: Deciphering the role of CD44 in Ewing sarcoma
E. Fernández-Tabanera

Conclusions and Final Remarks

12:10 - 13:30 **Lunch**